Mouse models for muscular dystrophies: an overview

Puffen, M. van; Lloyd, E.M.; Greef, J.C. de; Raz, V.; Willmann, R.; Grounds, M.D.

Mouse models for muscular dystrophies: an overview

Maaike van Putten[1],*, Erin M. Lloyd[2], Jessica C. de Greef[1], Vered Raz[1], Raffaella Willmann[3] and Miranda D. Grounds[2]

ABSTRACT

Muscular dystrophies (MDs) encompass a wide variety of inherited disorders that are characterized by loss of muscle tissue associated with a progressive reduction in muscle function. With a cure lacking for MDs, preclinical developments of therapeutic approaches depend on well-characterized animal models that recapitulate the specific pathology in patients. The mouse is the most widely and extensively used model for MDs, and it has played a key role in our understanding of the molecular mechanisms underlying MD pathogenesis. This has enabled the development of therapeutic strategies. Owing to advancements in genetic engineering, a wide variety of mouse models are available for the majority of MDs. Here, we summarize the characteristics of the most commonly used mouse models for a subset of highly studied MDs, collated into a table. Together with references to key publications describing these models, this brief but detailed overview would be useful for those interested in, or working with, mouse models of MD.

KEY WORDS: Disease pathology, Mouse models, Muscular dystrophy

Introduction

Muscular dystrophies (MDs) are a clinically and genetically heterogeneous group of inherited disorders. They are characterized by progressive muscle weakness affecting skeletal muscles, but some MDs involve cardiac and/or smooth muscles (Emery, 2002; Mercuri and Muntoni, 2013). Age of onset, disease severity and progression varies markedly between the different MDs. To date, more than 50 causative genes have been identified. Historically, MDs were classified based on the main clinical manifestations and the age of onset. Later, the mode of inheritance was also taken into account, resulting in further sub-classification of limb-girdle muscular dystrophy (LGMD) and congenital muscular dystrophy (CMD).

Importance of mouse models for studying disease mechanism and potential therapies

The availability of animal models of MDs plays a key role in studying disease pathology. Despite differences in some pathological hallmarks compared to humans, animal models have provided important insights into causal gene relationships and into the functional cellular and molecular mechanisms of disease

pathogenesis. Consequently, a variety of therapeutic approaches have been developed using these models for MDs. Animal models play a pivotal role in preclinical studies to progress therapies to the clinic, from proof-of-principle studies, dosage and efficacy studies to extended preclinical trials (Allamand, 2000; Durbeej and Campbell, 2002).

Mice are the most frequently used models of MDs, as they are easy and relatively inexpensive to breed and maintain in large numbers, and to handle, treat and genetically modify. They are ideal subjects for preclinical studies owing to their small body size, short gestation and life span, and the abundance of experimental reagents available, such as antibodies and expression constructs. In addition, the mouse genome is well characterized and is largely comparable to the human genome. Moreover, detailed natural life-history data are available for an increasing number of mouse strains, providing crucial information for the accurate design of preclinical studies. Especially in the last decade, the research community has highlighted the need for detailed natural life-history data from both MD patients and the mouse models. This call arose due to the failure of several drugs in clinical trials despite encouraging preclinical data (Kornegay et al., 2014; Straub and Mercuri, 2018). As such, multiple international initiatives aim to improve preclinical trial design and execution (Gordish-Dressman et al., 2018; Heslop et al., 2015; Nagaraju et al., 2009). The TREAT-NMD Alliance has coordinated the generation and maintenance of standard operating procedures (SOPs) for several widely used outcome measures for the most commonly used mouse models of Duchenne muscular dystrophy (DMD) (Nagaraju et al., 2009; Willmann et al., 2011a), spinal muscular atrophy (SMA) (Willmann et al., 2011b) and CMD (Saunier et al., 2016). Detailed information is available on the TREAT-NMD website (https://treat-nmd.org/research-overview/ preclinical-research/). These SOPs have now been downloaded worldwide more than 11,000 times in the last 7 years, and have been implemented in many research publications (Carlson et al., 2011; Mantuano et al., 2018; Mele et al., 2019; Tam et al., 2015; Zschüntzsch et al., 2016). It is hoped that implementation of the SOPs reduces intra- and inter-variability between complying laboratories. For mouse models of other MDs, these initiatives are either ongoing or planned.

In Table 1, we provide a detailed overview of the main disease characteristics of the most commonly used mouse models in preclinical research for nine MDs, with a focus on those used extensively in preclinical trials and those that were crucial to elucidate aspects of the pathology of each MD.

Technologies to generate mouse models for MDs

Naturally occurring dystrophic mouse strains, in which a spontaneous mutation results in an MD phenotype (e.g. *mdx*, A/J, SJL/J and *dy²ᴶ/ dy²ᴶ*), make up the minority of the available models. The majority of the mouse models have been genetically engineered, either by overexpressing the mutated gene or replacing the wild-type (WT) gene using a variety of non-targeted or targeted methods. Here, we

[1]Leiden University Medical Center, Department of Human Genetics, Leiden, 2333 ZA, The Netherlands. [2]The University of Western Australia, School of Human Sciences, Perth 6009, Australia. [3]University of Basel, Biozentrum, Basel, CH-4056, Switzerland.

*Author for correspondence (m.van_putten@lumc.nl)

M.v.P., 0000-0002-0683-8897; J.C.d.G., 0000-0002-2819-6098; V.R., 0000-0003-3152-1952; R.W., 0000-0002-5949-0900; M.D.G., 0000-0002-4530-9402

Table 1. Overview of mouse models available to study muscular dystrophies

Disease	Strain name	Transgenic/gene targeted	Genetic background	Protein affected	Skeletal muscle pathology	Heart pathology	Other phenotypes	Survival	Reference
Dystrophinopathies Duchenne MD	Mdx (C57BL/10ScSn-Dmd^mdx/J)	Spontaneous Premature stop codon exon 23 (3185 C>T)	C57BL/10ScSnJ Also available on C57BL/6J and DBA/2J genetic backgrounds	Dystrophin (Dp427 lacking)	Cycles of degeneration and regeneration from 3-8 weeks, stabilization with age. Muscle function and strength slightly impaired. Limited impairment of regenerative capacity. Histopathology consisting of necrosis, fibre size alterations, myogenesis, centralized nuclei, fibrosis and inflammation. Dia most affected, TA least affected.	Cardiomyopathy from 6 months onwards, extensive fibrosis.	Cognitive dysfunction	21-23 months	Bulfield et al., 1984; Gordish-Dressman et al., 2018; Veltrop et al., 2013
	Mdx^2cv (B6Ros.Cg-Dmd^mdx-2Cv/J)	ENU-mutagenesis A>T mutation in acceptor splice site in intron 42	C3H.X_25×C57BL/10 6Ros×C57BL/10 crossed to C57BL/6J	Dystrophin (Dp427+Dp260 lacking)	Pathology as per mdx, but larger variation in fibre size. Revertant fibre number comparable to mdx.	ND	Altered electroretinograms	21-23 months	Chapman et al., 1989; Cox et al., 1993
	Mdx^3cv (B6Ros.Cg-Dmd^mdx-3Cv/J)	ENU-mutagenesis T>A mutation in intron 65 that induced a cryptic splice site and frame-shift	C3H.X_25×C57BL/10 6Ros×C57BL/10 crossed to C57BL/6J	Dystrophin (express ~5% of WT of all isoforms, in skeletal muscles)	Express low dystrophin levels in all muscles. Pathology less severe than mdx, no revertant fibres.	ND	Reduced neonatal survival and poor breeder, most severely altered electroretinograms, altered spermatozoa, cognitive dysfunction	21-23 months	Cox et al., 1993
	Mdx^4cv (B6Ros.Cg-Dmd^mdx-4Cv/J)	ENU-mutagenesis 7925 C>T mutation stop codon exon 53	C3H.X_25×C57BL/10 6Ros×C57BL/10 crossed to C57BL/6J	Dystrophin (Dp427, Dp260 and Dp140 lacking)	10× fewer revertant fibres than mdx. Pathology as per mdx, but larger variation in fibre size.	ND	Altered electroretinograms	21-23 months	Cox et al., 1993
	Mdx^5cv (B6Ros.Cg-Dmd^mdx-5Cv/J)	ENU-mutagenesis 1306 A>T mutation exon 10 induced cryptic splice donor site and frame-shift	C3H.X_25×C57BL/10 6Ros×C57BL/10 crossed to C57BL/6J	Dystrophin (Dp427 lacking)	10× fewer revertant fibres than mdx, larger variation in fibre size. Pathology a bit more severe than mdx.	ND	None	21-23 months	Cox et al., 1993
	Mdx52 (Dmd^tm1Mok)	Targeted disruption Homologous recombination Point mutation exon 52	C57BL/6J	Dystrophin (Dp427, Dp260 and Dp140 lacking)	Pathology as per mdx, but fewer revertant fibres	Absent	Abnormal electro-retinograms	21-23 months	Araki et al., 1997
	hDMD/del52-mdx	TALENs: Partial deletion of exon 52 in hDMD gene Natural exon 23 stop mutation Dmd gene	DBA2×129 OLA×C57BL/6J	Murine and human dystrophin (Dp427, Dp260 and Dp140 lacking)	Pathology as per mdx	ND	None	21-23 months	Veltrop et al., 2018
	hDMD/del45-mdx	CRISPR-Cas9 Deletion exon 45 in hDMD gene Natural exon 23 stop mutation Dmd gene	DBA2×129 OLA×C57BL/6J Also available on DBA/2J genetic background	Murine and human dystrophin (Dp427, Dp260 and Dp140 lacking)	Pathology as per mdx	ND	None	21-23 months	Young et al., 2017
	Mdx-utm^−/− (Utm^tm1Ked Dmd^mdx/J)	Targeted disruption Construct lacking NH2 terminal exon of Utm (Deconinck et al., 1997a) Homologous recombination Removal of COOH-terminal of cysteine-rich region of Utm (Grady et al., 1997)	C57BL/6J	Dystrophin (Dp427) Utrophin (lacks both proteins)	Comparable pathology between both strains. Severe muscular dystrophy with altered fibre size, necrosis, central nucleation, fibrosis. No fat infiltration. Severely impaired muscle function, which deteriorates with age. Dia most affected, TA least affected. Histopathology more severe than mdx mouse.	Cardiomyopathy from 8-10 weeks onwards.	Severe kyphosis, weight loss, neuromuscular junction abnormalities (van der Pijl et al., 2016).	<20 weeks	Deconinck et al., 1997b; Grady et al., 1997
	Mdx/Cmah	Deletion exon 6 of Cmah^tm1Avr gene, loxP and Cre-mediated recombinase	C57BL/10ScSnJ	Dystrophin (Dp427)	More severe fibrosis of quad, gas and dia at 2 months of age compared to mdx.	Heart dysfunction from 3 months onwards.	Complement activation. Atypical growth and skeletal development.	50% lethality by 11 months of age.	Chandrasekharan et al., 2010
	Mdx^4cv-mTR^ko	Knockout of mTR	C57BL/6J	Dystrophin (Dp427, Dp260 and Dp140)	Impaired muscle function and fibrosis at 8 weeks.	At 32 weeks of age severe histological and functional pathology	Shortened telomeres	4-18 months	Chang et al., 2016; Sacco et al., 2010

Disease / Model	Mutation	Strain background	Protein (expression)	Muscle pathology	Heart pathology	Other	Lifespan	Reference
Dysferlinopathies **Limb girdle MD R2 dysferlin-related and Miyoshi MD** BLA/J (B6.A-Dysf^prmd/GeneJ)	Spontaneous ETn retrotransposon insertion in intron 4	C57BL/6J	Dysferlin (no expression)	Histological dystrophic features (some central myonuclei) observed by 4-5 months, with initial distal bias. Little myonecrosis. Histopathology is pronounced by 8 months, incl. loss of muscle mass and lipid deposition. Slow disease progression with limb girdle progression; psoas and quad most affected.	No evidence	None	Unaffected	Lostal et al., 2010
A/J	Spontaneous ETn retrotransposon insertion in intron 4	Inbred A/J Mutation arose in A/J colony in ~1980 (Ho et al., 2004)	Dysferlin (no expression)	Disease progression like BLA/J strain, but with an initial proximal bias. Abdominal muscles also show more rapid rate of muscle wasting. Quad most affected.	Very mild cardiomyopathy at 10 months. Cardiomyocyte membrane damage at intercalated disk and sarcoplasm (Chase et al., 2009).	Progressive loss of hearing, high incidence of lung adenomas and deficient in complement C5 (susceptible to infections)	Unaffected	Ho et al., 2004
SJL/J	Spontaneous splice site mutation in exon 45	Wild-derived strain of Swiss mice Recognised as dysferlin-deficient in ~1999 (Bittner et al., 1999)	Dysferlin (15% of WT levels)	Histological dystrophic features (some central myonuclei) observed at 2-4 months, with initial proximal bias. Histopathology pronounced ~6-8 months, including loss of muscle mass and lipid deposition. Quad most affected. Enhanced inflammation and faster disease progression compared to BLA/J and A/J.	No evidence	Aggressive behaviour, high incidence of lymphoma, and susceptibility to autoimmune diseases and viral infections	Unaffected	Bittner et al., 1999; Weller et al., 1997
129-Dyst^tm1Kcam/J	Neomycin resistance gene replacement removes last three coding exons including the transmembrane domain	129 Also available on C57BL/6J background	Dysferlin (no expression)	Histological dystrophic features (e.g. some central myonuclei) observed at 2 months. Pronounced histopathology by 8 months as above, with psoas most affected. Faster disease progression compared to BLA/J and A/J.	Extremely mild cardiomyopathy (fibrosis) from ~13 months; further deterioration after stress from downhill running (Han et al., 2007)	None	Unaffected	Bansal et al., 2003
Sarcoglycanopathies **Limb girdle MD R3 α-sarcoglycan-related** Sgca-null (Sgca^tm2Kcam)	Neomycin resistance gene replacement: removal of exons 2 and 3 of Sgca gene	Backcrossed on C57BL/6J	α-sarcoglycan (no expression)	Little fat infiltration detected. Muscle function deteriorates with age and is equally affected between genders.	No heart pathology	None	>12 months	Duclos et al., 1998; Pasteuning-Vuhman et al., 2017
Limb girdle MD R4 β-sarcoglycan-related Sgcb-null (B6.129-Sgcb^tm1Kcam/1J)	Neomycin resistance gene replacement: removal of exons 3-6 of Sgcb gene	(129X1/SvJx129S1/SvJ)F1-Kitl+	β-sarcoglycan (no expression)	Severe muscular dystrophy; hypertrophy, extensive calcification, fat infiltrations and fibrosis at 2 months. More severe pathology than Sgca-null model.	Severe cardiomyopathy. Necrosis from 9 weeks, and fibrosis from 30 weeks onwards.	Vascular irregularity in kidney	>12 months	Durbeej et al., 2000
Limb girdle MD R5 γ-sarcoglycan-related Sgcg-null (Sgcg^tm1Mcn)	Neomycin resistance gene replacement: removal of exon 2 of Sgcg gene	C57BL/6J	Γ-sarcoglycan (no expression)	Histopathology consisting of severe inflammation, fibrosis, necrosis, altered fibre sizes and central nucleation.	Severe cardiomyopathy at 20 weeks, including fibrosis. LV wall thickening.	None	50% lethality by 20 weeks of age	Hack et al., 1998
Sgcg-null	Neomycin resistance gene replacement: removal of exon 3 of Sgcg gene	C57BL/6J	Γ-sarcoglycan (no expression)	Progressive muscle hypertrophy and weakness. Fibre branching, necrosis and central nucleation in addition to muscle degeneration.	Subset of mice exhibit cardiomyocyte necrosis and fibrosis from 33 weeks onwards	None	>12 months	Sasaoka et al., 2003
521ΔT	CRISPR/Cas9 Deletion of single nucleotide in exon 6 (521ΔT)	DBA2/J	Γ-sarcoglycan (no expression)	Progressive dystrophic histopathology. Muscle atrophy, fibre size alterations, central nucleation, fibrosis. Severe impairment of muscle function.	Ventricular fibrosis at 4 months, but no alterations in echocardiogram	None	ND	Demonbreun et al., 2019
Limb girdle MD R6 δ-sarcoglycan-related Sgcd-null	Neomycin resistance gene replacement: removal of exon 2 of Sgcd gene	C57BL/6J	δ-sarcoglycan (no expression)	Histological features of MD: focal areas of necrosis/ fibrosis, inflammation. Impaired muscle function.	Electrocardiogram abnormalities from 8 weeks. Cardiomyopathy from 16 weeks, with reduced ejection fraction at 32 weeks (Bauer et al., 2008, 2010).	None	>12 months	Coral-Vazquez et al., 1999

Continued

Disease Models & Mechanisms

Table 1. Continued

Disease	Strain name	Transgenic/gene targeted	Genetic background	Protein affected	Skeletal muscle pathology	Heart pathology	Other phenotypes	Survival	Reference
	Sgcd-null (B6.129-Sgcd^tm1Mcn/J)	Neomycin resistance gene replacement: removal of exon 2 of Sgcd gene	129SvJ/129SvEms-+Ter/J	δ-sarcoglycan (no expression)	Impaired muscle function, which deteriorates with age. Histological features of MD: area of abundant necrosis, fibrosis, inflammation and calcification. Dia most affected, TA least affected. Muscle function more severe in males.	Fibrotic lesions from 12 weeks onwards. At 6 months fractional shortening, progressing to ventricular dysfunction at 12 months (Bauer et al., 2019).	None	50% survival at 28 weeks (Hack et al., 2000), in some but not all colonies (Pasteuning-Vuhman et al., 2017)	Hack et al., 2000; Pasteuning-Vuhman et al., 2017; Verhaart et al., 2019
Congenital MD with merosin deficiency MDC1A	Lama2^dy/dy w (B6.129S1(Cg)-Lama2^tm1Eeng/J)	Neomycin resistance gene replacement: removal of start-codon of Lama2 gene	C57BL/6J	Laminin α2 (no expression)	Severe muscular dystrophy, necrosis, hindlimb paralysis	No heart pathology	Reduced motility, weakness, demyelination of peripheral nervous system	5-12 weeks	Kuang et al., 1998b; Reinhard et al., 2017; Willmann et al., 2017
	Lama2^dy2J/dy2J (B6.WK-Lama2^dy-2J/J)	Spontaneous. Splice site mutation in LN domain.	C57BL/6J	Laminin α2 (reduced expression of truncated protein)	Muscle function impaired from 4 weeks. Hindlimb paralysis from 6 weeks. Respiration impaired from 15 weeks. Less affected than dy^W/dy^W and dy^3K/dy^3K models.	No heart pathology	Denervation and demyelination of peripheral nervous system	6-12 months	Pasteuning-Vuhman et al., 2018; Sunada et al., 1995; Xu et al., 1994
	Lama2^dy3k/dy3k (Lama2^tm1Stk)	Neomycin resistance gene replacement: removal of Lama2 gene	ICR	Laminin α2 (no expression)	Onset degeneration on postnatal day 9. Early fibrosis and severe muscle function impairment. Amelioration at 3 weeks, very severe muscular dystrophy.	No heart pathology	Myelination defects, impaired spermatogenesis, defective odontoblast differentiation	3-5 weeks	Gawlik et al., 2019; Miyagoe et al., 1997
Facioscapulo-humeral MD	D4Z4-2.5 (B6N.Cg-Tg(DUX4*)1Maar/J)	Transgenic (chromosome 17): 2.5 D4Z4 repeat units followed by the pLAM sequence (telomeric flanking region of D4Z4 which contains the 3' UTR of DUX4) with endogenous PAS.	C57BL/6NJ	Variable DUX4 expression in all tissues	No skeletal muscle pathology	No heart pathology	Mild hyperkeratosis >8-12 weeks; incomplete closure of eyelids and keratitis in 50% of mice	>12 months	Krom et al., 2013
	iDUX4pA (Hprt^tm1(tetO-DUX4/kyba)/J)	Transgenic [X chromosome; dox-inducible (i.p. injection)]: DUX4 genomic sequence followed by endogenous PAS. iDUX4pA mice must be crossed with HSA-rtTA/TRE-Cre mice for dox induction.	C57BL/6J	DUX4 expression in all tissues without dox. Higher DUX4 expression in skeletal muscles after dox.	No dox: Skeletal muscle pathology in males: smaller muscles, muscle function and locomotion impaired, reduced specific force. 5 mg/kg dox (daily): Skeletal muscle pathology in males and females: central nuclei, immune cell infiltration, fibrosis, smaller muscles, reduced absolute and specific force, reduced recovery after injury. TA least affected. 100 mg/kg dox (daily): Severe skeletal muscle pathology in males and females: many central nuclei, immune cell infiltration, severe fibrosis, muscle atrophy, limited recovery after injury. TA least affected.	No heart pathology	Skin hyperkeratosis and alopecia >1-2 weeks. Hearing impaired at higher frequencies. Males more affected.	Males 4 months Females >4 months (no dox).	Bosnakovski et al., 2017
	FLExDUX4 (B6(Cg)-Gt(ROSA)26Sor^tm1.1(DUX4*)Plj/J)	Transgenic [Rosa26 locus; tam-inducible (i.p. injection)]: DUX4 genomic sequence followed by endogenous PAS. FLExDUX4 mice must be crossed with Tg(ACTA1-cre/Esr1*)2Kesr mice for tam induction.	C57BL/6J	DUX4 expression in all tissues without tam. Higher DUX4 expression in skeletal muscles after tam.	No tam: Limited skeletal muscle pathology: central nuclei >10-12 weeks. 5 mg/kg tam (1×): Skeletal muscle pathology: central nuclei, apoptosis, immune cell infiltrations, decline in treadmill performance (peak 2 weeks after tam, partial recovery 4 weeks after tam). Females more affected. 10 mg/kg tam (2×): Severe skeletal muscle pathology: central nuclei, apoptosis, immune cell infiltration, fibrosis, major decline in treadmill performance (no signs of recovery, immobile d9). Females more affected.	No heart pathology	Mild alopecia >2 weeks and reduced size >8-12 weeks. Females more affected.	>18 months (no tam)	Jones and Jones, 2018; Jones et al., 2018 preprint

Disease Models & Mechanisms

Disease	Model	Modification	Strain	Expression	Pathology	Heart		Onset/lifespan	Reference
	TIC-DUX4 (B6.129S6-Gt(ROSA)26Sor^tm1(DUX4)Sqh/J)	Transgenic [Rosa26 locus; tam-inducible (oral gavage)]: DUX4 genomic sequence followed by endogenous PAS and bovine growth hormone PAS.	C57BL/6J	Sporadic DUX4 expression in skeletal muscles without tam. Higher DUX4 expression in skeletal muscles after tam.	No tam: Very mild skeletal muscle pathology: central nuclei, immune cell infiltration, smaller muscles, reduced absolute force >18 months. 5 mg/kg tam (1× week): Progressive skeletal muscle pathology: central nuclei 1 month, central nuclei, immune cell infiltration, reduced absolute and specific force 2 months, many central nuclei 3-4 months (partial recovery for activity 3-4 months). 150 mg/kg tam (2×): Severe skeletal muscle pathology: degenerative fibres, immune cell infiltration, reduced absolute and specific force (no signs of recovery, non-ambulatory d10).	No heart pathology	None	>18 months (no tam)	Giesige et al., 2018
Oculopharyngeal MD	A17.1	Constitutively over expression Ala17-hPABPN1	FVB/N	PABPN1	PABPN1 aggregates, muscle atrophy in fast muscles. Muscle weakness from 18 weeks onwards.	No heart pathology	None	Unaffected	Trollet et al., 2010
	PABPN1^+/A17	Conditional PABPN1^+/A17 knock-in	C57BL/6J	PABPN1	A muscle-specific change in myofibre CSA. Central nuclei.	No heart pathology	None	Unaffected	Davies et al., 2006
	PABPN1^+/Δ	Conditional PABPN1 knockout	C57BL/6J	PABPN1 (express 50% of WT levels)	Small changes in muscle-specific change in myofibre CSA	No heart pathology	None	Unaffected	Vest et al., 2017

CSA, cross-sectional area; dia, diaphragm; dox, doxycycline; ENU, N-ethylnitrosourea; gas, gastrocnemius; i.p., intraperitoneal; LV, left ventricle; ND, not determined; PAS, poly-adenylation signal; quad, quadriceps; TA, tibialis anterior; tam, tamoxifen; UTR, untranslated region.

briefly explain each of these approaches. For more comprehensive reviews on gene-editing techniques for the generation of mouse models, we refer the reader to Gurumurthy and Lloyd (2019), Hall et al. (2009) and Justice et al. (2011).

Non-targeted gene disruption
Some strains described in Table 1 have been generated using a non-targeted approach, by chemicals that randomly induce point mutations throughout the genome. N-ethylnitrosourea (ENU) is a commonly used mutagen that randomly mutates the DNA with a frequency of 1 mutation per 700 loci (Stottmann and Beier, 2014). The offspring of ENU-exposed mice are then screened for a marker for the disease: for instance, in the case of $mdx^{2–5cv}$ models, female offspring were screened for muscle dystrophy by assessing creatine kinase (CK) levels in blood, a marker of muscle leakiness (Chapman et al., 1989; Cox et al., 1993; Im et al., 1996). Carrier mice with elevated CK levels were then further investigated for muscle pathology, and their genomes were subsequently sequenced to identify the specific mutation.

Targeted gene disruption
The majority of the knockout mouse models that are available for MDs were generated via gene targeting. There are several protocols, but they all employ the cell-intrinsic homologous recombination DNA repair mechanism to insert a targeting vector in a homologous genetic locus of interest (Hall et al., 2009). Consequently, cells lack the targeted sequences (i.e. one or multiple exons) and fail to express the corresponding protein. The procedure requires a vector, which has a specific make-up depending on the method used. Generally, this vector contains the sequences of the regions flanking the exon(s) of interest and, in the middle of this, a drug selection marker (like that for neomycin resistance), which replaces the exon(s) of interest in the cell and allows for cell selection (Bouabe and Okkenhaug, 2013). Some vectors also contain recombinase-binding elements such as LoxP or Flp recombination target sites. Via electroporation, the vector is introduced into murine embryonic stem cells, which are then cultured and selected based on the resistance for the selection marker of choice. The resistant cells are then injected into a mouse blastocyst from which a knockout offspring develops.

The transcription activator-like effector nuclease (TALEN) technology (Cermak et al., 2011) has been used to generate the hDMD/del52-mdx model (Veltrop et al., 2018). For this model, TALENs induced double-strand breaks in the region of interest of a gene. Consequently, cells repaired these breaks through the non-homologous end-joining (NHEJ) DNA repair process. This is the dedicated repair mechanism to restore double-strand DNA breaks in non-dividing cells, in which DNA ends are ligated without the use of a template in an error-prone manner that typically disrupts the open reading frame, knocking out the gene of interest.

Recently, CRISPR/Cas9 technology has been used to rapidly engineer precise human mutations, generating many new mouse models (Cong et al., 2013). Several variations of the CRISPR/Cas9 system have been used, e.g. to generate the hDMD/del45-mdx (Young et al., 2017) and Dmddel8-34 models for DMD (Egorova et al., 2019), and the 521ΔT model for LGMD R5 γ-sarcoglycan-related (Demonbreun et al., 2019). For the DMD models, guide RNAs were designed to target the region of interest and to guide the Cas9 nuclease to this region to execute the cuts. NHEJ ensured the deletion of this particular region. The 521ΔT model for LGMD R5 γ-sarcoglycan-related (Demonbreun et al., 2019), on the other hand, is a knock-in model: here, a mutated part of exon 6 was used as repair template, which replaced the intact intrinsic exon 6 sequence upon a CRISPR/Cas9-mediated DNA break and homology-directed repair.

Dystrophinopathies

DMD is an X-linked progressive disorder caused by mutations in the *DMD* gene that result in the lack or defective forms of the structural muscle protein dystrophin and manifests in young children. The most commonly used DMD model is the *mdx* mouse (Bulfield et al., 1984; Willmann et al., 2009) and, to a lesser extent, its genetic variants mdx^{2cv}, mdx^{3cv}, mdx^{4cv}, mdx^{5cv} (Cox et al., 1993), *mdx*52 (Araki et al., 1997) and DMD^{null} (Kudoh et al., 2005). *Mdx* mice are primarily affected from 3 weeks onwards, when cycles of muscle necrosis and regeneration occur during the intense growth period. These cycles continue until ∼12 weeks of age, when 80% of myofibres have central myonuclei indicating past events of necrosis and regeneration (Coulton et al., 1988). Thereafter, the pathology stabilizes and adult mice have greatly reduced incidence of myonecrosis and mildly increasing fibrosis (Grounds, 2008). The diaphragm is more severely affected than other skeletal muscles because of impaired regeneration. Unlike in DMD patients, fat infiltrates are rarely seen in *mdx* mice. Cardiomyopathy is observed in *mdx* mice from ∼6 months of age.

To allow the use of human-specific sequences when investigating the potential of gene therapies (Verhaart and Aartsma-Rus, 2019; Aartsma-Rus and van Putten, 2020), mice carrying mutations in the human *DMD* gene have been generated [e.g. with a deletion of exon 45 in hDMD/del45-*mdx* (Young et al., 2017) or exon 52 in hDMD/del52-*mdx* strains (Veltrop et al., 2018)]. Natural life-history data are not yet available for these new humanized mouse strains, but their pathology appears to be similar to that of the classic *mdx* mouse (Veltrop et al., 2018; Young et al., 2017).

The *mdx* model is limited by its mild disease presentation and only slightly reduced lifespan. To overcome this, several additional mutations were crossed onto the *mdx* background generating double knockout mice. The *mdx-utrn*$^{-/-}$ mouse, which lacks dystrophin and its homologue utrophin, is most widely used (Deconinck et al., 1998; Grady et al., 1997). As utrophin is important for neuromuscular transmission, this double knockout is more severely affected and dies before ∼13 weeks of age owing to muscle weakness and respiratory problems. The *mdx-utrn*$^{-/-}$ mice also develop kyphosis and heart pathology at <8 weeks of age. These mice are therefore more useful to study survival. However, when evaluating drugs targeting pathology in this model, it is unknown whether a potential improvement is due to addressing pathology induced by lack of dystrophin or that induced by lack of utrophin; thus, it is difficult to determine their translational relevance to DMD.

Two newer double knockouts are the *mdx*/Cmah$^{-/-}$ (Chandrasekharan et al., 2010) and mdx^{4cv}/mTR^{ko} strains (Sacco et al., 2010). Unlike mice, humans carry an inactivating deletion in the cytidine monophospho-*N*-acetylneuraminic acid hydroxylase (*CMAH*; also known as *CMAHP*) gene, which prevents glycosylation with *N*-glycolylneurominic acid. The *mdx*/Cmah$^{-/-}$ model also has a 'humanized' mutation in the *Cmah* gene and exhibits a more severe pathology (Chandrasekharan et al., 2010). This double knockout mouse also has impaired life span, with a 50% survival rate at 11 months of age. They have abundant fibrosis in skeletal muscles from 6 weeks onwards, and impaired heart function at 3 months (Betts et al., 2019). Growth and skeletal development is, however, atypical and does not reflect the human DMD trajectory (Wood et al., 2020).

The mdx^{4cv}/mTR^{ko} mouse lacks the RNA component of telomerase and consequently has shortened telomeres, which are closer to the size observed in humans (Sacco et al., 2010). Telomeres protect chromosome ends from deterioration, and their length dictates the replicative lifespan of cells. It was hypothesized that the excellent regenerative capacity of *mdx* mice partly results from long telomeres in mice, and thus shortening the telomeres would impair muscle regeneration. The regenerative capacity of mdx^{4cv}/mTR^{ko} mice is indeed impaired. Skeletal muscle function is affected at 8 weeks, with severe cardiac dysfunction observed in 32-week-old mdx^{4cv}/mTR^{G2} mice (Mourkioti et al., 2013). As telomere length shortens with each generation of mdx^{4cv}/mTR mice, the lifespan of second-generation mice is shorter than that of the first generation (Sacco et al., 2010). Nonetheless, the mdx^{4cv}/mTR^{ko} strain has not yet been widely used in the research community.

Another way to exacerbate the disease pathology of *mdx* mice is to cross them onto a different genetic background (McGreevy et al., 2015). For example, the dystropathology worsens when *mdx* mice are bred on the DBA2/J background. The muscle function of this strain, called D2-*mdx*, is severely affected; their muscles are atrophic with extensive fibrosis and initial calcification that largely disappears with age (Coley et al., 2016; Gordish-Dressman et al., 2018; van Putten et al., 2019). Lastly, there are also several immune-deficient *mdx* strains, and *mdx* strains with mutations in additional genes as described in McGreevy et al. (2015). Owing to space restrictions, we did not include these in Table 1.

Dysferlinopathies

Dysferlinopathies are caused by lack of functional dysferlin, a membrane-associated calcium-binding protein involved in membrane repair. The pathologies usually manifest in young adults as Myoshi myopathy or LGMD R2 dysferlin-related (previously known as LGMD2B; Straub et al., 2018). In general, dysferlin-deficient (dysf$^{-/-}$) mice mimic human dysferlinopathies, show a comparable disease progression with late-onset and similar, though milder, histopathological features, including loss of muscle mass, lipid droplets within slow twitch myofibres, adipocyte replacement of myofibres and inflammation (Grounds et al., 2014; Hornsey et al., 2013; https://www.jain-foundation.org/scientific-resources/research-tools/mouse-models-dysferlin-deficiency). Symptoms manifest in a muscle-specific manner, with the psoas and quadriceps muscles being some of the most affected by ∼8 months of age.

The most commonly studied dysf$^{-/-}$ models are the naturally occurring A/J (A/J$^{dysf-/-}$), SJL/J (SJL/J$^{dysf-/-}$) and BLA/J (B6.A-Dysf^{prmd}/GeneJ) mice. In addition, genetically modified knockout strains are also available; for example, the 129-Dysf^{tm1Kcam}/J strain, which is also available in a C57BL/6J background (B6.129-Dysf^{tm1Kcam}/J).

Both the A/J and SJL/J mice have impairments that are not observed in dysferlinopathy patients or other dysf$^{-/-}$ mice (Ho et al., 2004). These include poor fertility and susceptibility to infection, which are proposed to be because of unknown modifiers within the genetic backgrounds rather than the dysferlin deficiency itself (Doetschman, 2009). Thus, the A/J and SJL/J dysf$^{-/-}$ mice were backcrossed onto the better-defined genetic backgrounds, C57BL/6J (producing the BLA/J mouse) and C57BL/10J strains, respectively; also providing each new strain with a genetically defined dysferlin-positive WT control.

Earlier studies, many of which were conducted before these strains were recognized as dysferlin-deficient, used A/J and SJL/J mice (identified by 2004 and 1999, respectively; see Table 1). More recently, the BLA/J mouse has become the more popular model owing to its similar phenotype to other dysf$^{-/-}$ models, reduced susceptibility to infections and the well-studied C57BL/6J background (Lostal et al., 2010).

Increased lipofuscin, a classical measure of cumulative oxidative damage, is an early histological change in dysf$^{-/-}$ muscles, detected at

3 months in A/J mice (Terrill et al., 2013). Marked histopathology is evident in selected muscles (psoas>quadriceps) by 8 months in all dysf⁻/⁻ mice, with replacement of myofibres by adipocytes, which is more pronounced in older mice – studied up to 29 months of age (Albrecht et al., 2011; Hornsey et al., 2013; Terrill et al., 2013). However, the replacement of myofibres by adipocytes is not readily explained by myonecrosis, as this is relatively low (Terrill et al., 2013). The presence of conspicuous lipid droplets within dysf⁻/⁻ myofibres of rodents and humans is recognized as a striking feature (Demonbreun et al., 2014; Grounds et al., 2014). Recent lipidomic studies in young BLA/J mice showed marked changes in lipid metabolism and lipid composition of dysf⁻/⁻ muscles (Haynes et al., 2019).

Hornsey et al. provide a good review of the classic dysf⁻/⁻ mouse models (Hornsey et al., 2013), and details of many dysf⁻/⁻ strains are further provided on the Jain Foundation webpage (https://www. jain-foundation.org/scientific-resources/research-tools/mouse-models-dysferlin-deficiency).

Dysf⁻/⁻ mice have also been crossed with many other strains that lack specific genes to further understand the role of dysferlin and associated proteins in disease pathogenesis, for example the C3-deficient (Han et al., 2010), dystrophin-deficient *mdx* (Han et al., 2011), myoferlin-null (Demonbreun et al., 2014), annexin A2 knockout (Defour et al., 2017) and ApoE-null mice (Sellers et al., 2018).

Sarcoglycanopathies

The α-, β-, γ- and δ-sarcoglycans are structural muscle proteins that are absent in sarcoglycanopathy patients, underlying progressive muscle wasting that manifests as LGMD R3, R4, R5 and R6, respectively (previously known as 2D, 2E, 2C and 2F). In sarcoglycanopathy patients, the medium age of onset is 6-8 years. The *Sgca*-null, *Sgcb*-null, *Sgcg*-null and *Sgcd*-null (Coral-Vazquez et al., 1999; Hack et al., 2000) mice are the classic models used to study the pathology of the α-, β-, γ- and δ-sarcoglycanopathies, respectively. These models display progressive muscle pathology and functional impairments of variable severity starting at 1 week of age, thereby emulating the human disease fairly accurately. Notably, all sarcoglycan-null models except the *Sgca*-null mice develop a cardiac phenotype from as early as 8 weeks (Coral-Vazquez et al., 1999; Durbeej et al., 2000; Hack et al., 1998).

As in the *mdx* strain, the pathology of *Sgcg*-null mice is more severe when crossed onto the DBA2/J genetic background (Heydemann et al., 2005). Recently, a novel variation of the *Sgcg*-null mouse has been generated, which, for the first time, allows investigation of exon skipping therapy for R5 γ-sarcoglycan-related LGMD patients (LGMD2C). The 521ΔT mouse has a single nucleotide deletion in exon 6, corresponding to the most common mutation found in patients (Demonbreun et al., 2019). Multi-skipping of exons 4, 5, 6 and 7 is required to restore the open reading frame, resulting in the expression of mini-γ sarcoglycan in these mice.

Congenital muscular dystrophies (CMDs)

CMDs are a large group of muscular dystrophies with an early age of onset. Here, we focus on two common CMDs that manifest at birth. In humans, defects in the α2 chain of laminin (also called merosin) and α-dystroglycan underlie merosin-deficient congenital muscular dystrophy type 1A (MDC1A) and the dystroglycanopathies, respectively (Durbeej, 2015; Gawlik and Durbeej, 2011; Saunier et al., 2016).

For laminin α2-deficiency, five mouse models have been regularly studied, with three described in Table 1: two knockouts (dy^{3K}/dy^{3K} and dy^w/dy^w) (Kuang et al., 1998a; Miyagoe et al., 1997), two spontaneous models (*dy/dy* and dy^{2J}/dy^{2J}) (Meier and

Southard, 1970; Michelson et al., 1955) and an ENU-induced model (dy^{7J}/dy^{7J}) (Patton et al., 2008). They have mild to moderate muscular dystrophy evident at birth, with peripheral neuropathy and severely impaired life expectancy (5-12 weeks for dy^w/dy^w and 3 weeks for dy^{3K}/dy^{3K} mice), except for the dy^{2J}/dy^{2J} and dy^{7J}/dy^{7J} strains (life span of >6 months). The dy^w/dy^w strain is most commonly used, and the TREAT-NMD consortium have generated several SOPs for this model (https://treat-nmd.org/research-overview/preclinical-research/sops-for-cmd-animal-models/).

Detailed information on dystroglycanopathy models is provided on the Cure-CMD webpage (https://www.curecmd.org/resources-for-scientists).

Facioscapulohumeral muscular dystrophy (FSHD)

FSHD primarily affects the facial, shoulder and upper arm muscles. There is a large spread in the age of onset. Although most patients develop symptoms at ~20 years of age, manifestations have been reported from infancy to 50 years of age. FSHD is caused by the epigenetic de-repression of the *DUX4* retrogene encoded within each unit of the D4Z4 macrosatellite repeat array. The complex underlying genetics (Daxinger et al., 2015) have prevented the generation of a single mouse model that would represent the genetic and pathologic aspects of the human disease. There are several mouse models available where each recapitulates only specific aspects of the disease (Lek et al., 2015). As the D4Z4 repeat array encoding the *DUX4* retrogene is specific to old-world primates, meaning that DUX4 is not expressed in mice (Leidenroth and Hewitt, 2010), this required the introduction of an exogenous genetic *DUX4* construct. The first FSHD mouse model, the D4Z4-2.5 mouse, carries a contracted pathogenic FSHD allele of two and a half copies of the D4Z4 repeat unit. DUX4 expression can be detected in both skeletal muscles and non-muscle tissues and the D4Z4 locus is hypomethylated, as in FSHD patients. However, the mice do not present muscle weakness or wasting, which may partly be explained by the very low DUX4 expression levels in their skeletal muscles (Krom et al., 2013). More recently, several DUX4-inducible mice have been generated, which consequently show a dose-dependent severity of muscle histopathology and functional impairments (Bosnakovski et al., 2017; Giesige et al., 2018; Jones and Jones, 2018). It has, however, become apparent that the activation of the downstream targets of *DUX4* in mice differs from that in humans. Finally, several xenograft models are also available, in which skeletal muscle tissue from FSHD patients (Chen et al., 2016; Zhang et al., 2014) or muscle precursor cells (Mueller et al., 2019; Sakellariou et al., 2016) are transplanted into a muscle of the mouse.

Oculopharyngeal muscular dystrophy (OPMD)

OPMD is a late-onset monogenic myopathy primarily affecting the eyelid and pharyngeal muscle groups, with symptom manifestation from 40-60 years of age. The genetic cause of the disease is an expansion of the alanine track at the N-terminus end of the gene encoding for poly(A) binding protein nuclear 1 (*PABPN1*). OPMD has been identified throughout the world. Most reported cases are autosomal dominant, but several recessive cases have also been reported (Brais, 2009; de Leeuw et al., 2019). On the protein level, the alanine expansion varies between +1 and +8 over the non-pathogenic 10 alanine track. The expanded PABPN1 forms insoluble nuclear aggregates, which represent the histopathological hallmark of the disease (Trollet et al., 1993). The first mouse models for OPMD were generated with a high and constitutive overexpression of the 17 alanine-expanded PABPN1, of which the A17.1 mouse is the most well-studied model (Davies et al., 2010). Studies in this mouse and in

cellular models that were generated with overexpression of the expanded PABPN1 showed induction of cell death (Davies et al., 2006, 2010). However, cell death is not observed in the muscles of OPMD patients. Moreover, unlike the age-associated disease progression in OPMD patients, progression of muscle pathology in the A17.1 mouse is attenuated with age (Trollet et al., 2010). Interventions aimed at reducing PABPN1 aggregation were beneficial in mouse models that were generated by high overexpression. Whether these interventions are also beneficial for OPMD patients remains unresolved. Recently, Vest et al. generated a knock-in mouse model of Ala17, which captures some of OPMD pathological hallmarks (Vest et al., 2017). Additional studies in these mice are required to assess whether this is a good model for OPMD. So far, it is unclear whether PABPN1 aggregates are toxic and directly cause muscle weakness in OPMD. Several studies demonstrated that when PABPN1 expression levels are significantly reduced, below a certain threshold, it leads to muscle atrophy and wasting (Olie et al., 2019; Riaz et al., 2016; Vest et al., 2017). In muscles of OPMD patients, levels of PABPN1 correlate with disease progression (Anvar et al., 2013). It has been suggested that muscle weakness in OPMD is caused by a combination of accumulation and aggregation of expanded PABPN1 and an age-associated reduction in PABPN1 expression levels, which together reduce the availability of normal PABPN1 below a functional threshold (Raz and Raz, 2014). However, thus far, there is no animal model that emulates this combinatorial condition as in OPMD patients.

Conclusions

The availability of a variety of MD mouse models has greatly improved our understanding of pathogenesis and enabled the (pre)clinical development of several therapeutic approaches. Although these models allowed unprecedented opportunities for fundamental and applied research, their ever-increasing number also adds to the complexity of selecting the most appropriate model for a particular research question. The suitability of a certain model not only depends on the existence of the same genetic defect, but also on how well it emulates specific aspects of the human disease. Unfortunately, many MD mouse models are limited in their presentation of the human pathologies. These limitations, therefore, also add to the fact that the effects of a drug observed in mice may not necessarily predict the outcome in the clinical setting. To partly overcome these issues, the availability of natural life-history data for mouse models and of standardized operational procedures for *in vivo* outcome measures are pivotal for accurate study design and execution of high-quality preclinical research. Fortunately, these issues have received more attention in the last decade and are now in place for some MDs.

This article is part of a special subject collection 'A Guide to Using Neuromuscular Disease Models for Basic and Preclinical Studies', which was launched in a dedicated issue guest edited by Annemieke Aartsma-Rus, Maaike van Putten and James Dowling. See related articles in this collection at http://dmm.biologists.org/collection/neuromuscular.

References

Aartsma-Rus, A. and van Putten, M. (2020). The use of genetically humanized animal models for personalized medicine approaches. *Dis. Model. Mech.* **13**, dmm041673. doi:10.1242/dmm.041673

Albrecht, D. E., Garg, N., Rufibach, L. E., Williams, B. A., Monnier, N., Hwang, E. and Mittal, P. (2011). 4th annual dysferlin conference 11-14 september 2010, Washington, USA. *Neuromuscul. Disord.* **21**, 304-310. doi:10.1016/j.nmd.2011.02.001

Allamand, V. (2000). Animal models for muscular dystrophy: valuable tools for the development of therapies. *Hum. Mol. Genet.* **9**, 2459-2467. doi:10.1093/hmg/9.16.2459

Anvar, S. Y., Raz, Y., Verway, N., van der Sluijs, B., Venema, A., Goeman, J. J., Vissing, J., van der Maarel, S. M., 't Hoen, P. A. C., van Engelen, B. G. M. et al. (2013). A decline in PABPN1 induces progressive muscle weakness in oculopharyngeal muscle dystrophy and in muscle aging. *Aging* **5**, 412-426. doi:10.18632/aging.100567

Araki, E., Nakamura, K., Nakao, K., Kameya, S., Kobayashi, O., Nonaka, I., Kobayashi, T. and Katsuki, M. (1997). Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in duchenne muscular dystrophy. *Biochem. Biophys. Res. Commun.* **238**, 492-497. doi:10.1006/bbrc.1997.7328

Bansal, D., Miyake, K., Vogel, S. S., Groh, S., Chen, C.-C., Williamson, R., McNeil, P. L. and Campbell, K. P. (2003). Defective membrane repair in dysferlin-deficient muscular dystrophy. *Nature* **423**, 168-172. doi:10.1038/nature01573

Bauer, R., MacGowan, G. A., Blain, A., Bushby, K. and Straub, V. (2008). Steroid treatment causes deterioration of myocardial function in the δ-sarcoglycan-deficient mouse model for dilated cardiomyopathy. *Cardiovasc. Res.* **79**, 652-661. doi:10.1093/cvr/cvn131

Bauer, R., Blain, A., Greally, E., Bushby, K., Lochmüller, H., Laval, S., Straub, V. and MacGowan, G. A. (2010). Intolerance to β-blockade in a mouse model of δ-sarcoglycan-deficient muscular dystrophy cardiomyopathy. *Eur. J. Heart Fail.* **12**, 1163-1170. doi:10.1093/eurjhf/hfq129

Bauer, R., Enns, H., Jungmann, A., Leuchs, B., Volz, C., Schinkel, S., Koch, W. J., Raake, P. W., Most, P., Katus, H. A. et al. (2019). Various effects of AAV9-mediated βARKct gene therapy on the heart in dystrophin-deficient (mdx) mice and δ-sarcoglycan-deficient (Sgcd−/−) mice. *Neuromuscul. Disord.* **29**, 231-241. doi:10.1016/j.nmd.2018.12.006

Betts, C. A., McClorey, G., Healicon, R., Hammond, S. M., Manzano, R., Muses, S., Ball, V., Godfrey, C., Merritt, T. M., Van Westering, T. et al. (2019). Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment. *Hum. Mol. Genet.* **28**, 396-406. doi:10.1093/hmg/ddy346

Bittner, R. E., Anderson, L. V. B., Burkhardt, E., Bashir, R., Vafiadaki, E., Ivanova, S., Raffelsberger, T., Maerk, I., Höger, H., Jung, M. et al. (1999). Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B [2]. *Nat. Genet.* **23**, 141-142. doi:10.1038/13770

Bosnakovski, D., Chan, S. S. K., Recht, O. O., Hartweck, L. M., Gustafson, C. J., Athman, L. L., Lowe, D. A. and Kyba, M. (2017). Muscle pathology from stochastic low level DUX4 expression in an FSHD mouse model. *Nat. Commun.* **8**, 550. doi:10.1038/s41467-017-00730-1

Bouabe, H. and Okkenhaug, K. (2013). Gene targeting in mice: a review. *Methods Mol. Biol.* **1064**, 315-336. doi:10.1007/978-1-62703-601-6_23

Brais, B. (2009). Oculopharyngeal muscular dystrophy: a polyalanine myopathy. *Curr. Neurol. Neurosci. Rep.* **9**, 76-82. doi:10.1007/s11910-009-0012-y

Bulfield, G., Siller, W. G., Wight, P. A. and Moore, K. J. (1984). X chromosome-linked muscular dystrophy (mdx) in the mouse. *Proc. Natl. Acad. Sci. USA* **81**, 1189-1192. doi:10.1073/pnas.81.4.1189

Carlson, C. G., Bruemmer, K., Sesti, J., Stefanski, C., Curtis, H., Ucran, J., Lachey, J. and Seehra, J. S. (2011). Soluble activin receptor type IIB increases forward pulling tension in the mdx mouse. *Muscle Nerve* **43**, 694-699. doi:10.1002/mus.21944

Cermak, T., Doyle, E. L., Christian, M., Wang, L., Zhang, Y., Schmidt, C., Baller, J. A., Somia, N. V., Bogdanove, A. J. and Voytas, D. F. (2011). Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. *Nucleic Acids Res.* **39**, 7879. doi:10.1093/nar/gkr739

Chandrasekharan, K., Yoon, J. H., Xu, Y., DeVries, S., Camboni, M., Janssen, P. M. L., Varki, A. and Martin, P. T. (2010). A human-specific deletion in mouse Cmah increases disease severity in the mdx model of duchenne muscular dystrophy. *Sci. Transl. Med.* **2**, 42ra54. doi:10.1126/scitranslmed.3000692

Chang, A. C. Y., Ong, S.-G., LaGory, E. L., Kraft, P. E., Giaccia, A. J., Wu, J. C. and Blau, H. M. (2016). Telomere shortening and metabolic compromise underlie dystrophic cardiomyopathy. *Proc. Natl. Acad. Sci. USA* **113**, 13120-13125. doi:10.1073/pnas.1615340113

Chapman, V. M., Miller, D. R., Armstrong, D. and Caskey, C. T. (1989). Recovery of induced mutations for X chromosome-linked muscular dystrophy in mice. *Proc. Natl. Acad. Sci. USA* **86**, 1292-1296. doi:10.1073/pnas.86.4.1292

Chase, T. H., Cox, G. A., Burzenski, L., Foreman, O. and Shultz, L. D. (2009). Dysferlin deficiency and the development of cardiomyopathy in a mouse model of limb-girdle muscular dystrophy 2B. *Am. J. Pathol.* **175**, 2299-2308. doi:10.2353/ajpath.2009.080930

Chen, J. C. J., King, O. D., Zhang, Y., Clayton, N. P., Spencer, C., Wentworth, B. M., Emerson, C. P. and Wagner, K. R. (2016). Morpholino-mediated

knockdown of DUX4 toward facioscapulohumeral muscular dystrophy therapeutics. *Mol. Ther.* **24**, 1405-1411. doi:10.1038/mt.2016.111

Coley, W. D., Bogdanik, L., Vila, M. C., Yu, Q., Van Der Meulen, J. H., Rayavarapu, S., Novak, J. S., Nearing, M., Quinn, J. L., Saunders, A. et al. (2016). Effect of genetic background on the dystrophic phenotype in mdx mice. *Hum. Mol. Genet.* **25**, 130-145. doi:10.1093/hmg/ddv460

Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A. et al. (2013). Multiplex genome engineering using CRISPR/Cas systems. *Science* **339**, 819-823. doi:10.1126/science.1231143

Coral-Vazquez, R., Cohn, R. D., Moore, S. A., Hill, J. A., Weiss, R. M., Davisson, R. L., Straub, V., Barresi, R., Bansal, D., Hrstka, R. F. et al. (1999). Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy. *Cell* **98**, 465-474. doi:10.1016/S0092-8674(00)81975-3

Coulton, G. R., Morgan, J. E., Partridge, T. A. and Sloper, J. C. (1988). The mdx mouse skeletal muscle myopathy: I. A histological, morphometric and biochemical investigation. *Neuropathol. Appl. Neurobiol.* **14**, 53-70. doi:10.1111/j.1365-2990.1988.tb00866.x

Cox, G. A., Phelps, S. F., Chapman, V. M. and Chamberlain, J. S. (1993). New mdx mutation disrupts expression of muscle and nonmuscle isoforms of dystrophin. *Nat. Genet.* **4**, 87-93. doi:10.1038/ng0593-87

Davies, J. E., Sarkar, S. and Rubinsztein, D. C. (2006). Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy. *Hum. Mol. Genet.* **15**, 23-31. doi:10.1093/hmg/ddi422

Davies, J. E., Rose, C., Sarkar, S. and Rubinsztein, D. C. (2010). Cystamine suppresses polyalanine toxicity in a mouse model of oculopharyngeal muscular dystrophy. *Sci. Transl. Med.* **2**, 34ra40. doi:10.1126/scitranslmed.3000723

Daxinger, L., Tapscott, S. J. and van der Maarel, S. M. (2015). Genetic and epigenetic contributors to FSHD. *Curr. Opin. Genet. Dev.* **33**, 56-61. doi:10.1016/j.gde.2015.08.007

de Leeuw, R. H., Garnier, D., Kroon, R. M. J. M., Horlings, C. G. C., de Meijer, E., Buermans, H., van Engelen, B. G. M., de Knijff, P. and Raz, V. (2019). Diagnostics of short tandem repeat expansion variants using massively parallel sequencing and componential tools. *Eur. J. Hum. Genet.* **27**, 400-407. doi:10.1038/s41431-018-0302-4

Deconinck, A. E., Potter, A. C., Tinsley, J. M., Wood, S. J., Vater, R., Young, C., Metzinger, L., Vincent, A., Slater, C. R. and Davies, K. E. (1997a). Postsynaptic abnormalities at the neuromuscular junctions of utrophin-deficient mice. *J. Cell Biol.* **136**, 883-894. doi:10.1083/jcb.136.4.883

Deconinck, A. E., Rafael, J. A., Skinner, J. A., Brown, S. C., Potter, A. C., Metzinger, L., Watt, D. J., Dickson, J. G., Tinsley, J. M. and Davies, K. E. (1997b). Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. *Cell* **90**, 717-727. doi:10.1016/S0092-8674(00)80532-2

Deconinck, N., Rafael, J. A., Beckers-Bleukx, G., Kahn, D., Deconinck, A. E., Davies, K. E. and Gillis, J. M. (1998). Consequences of the combined deficiency in dystrophin and utrophin on the mechanical properties and myosin composition of some limb and respiratory muscles of the mouse. *Neuromuscul. Disord.* **8**, 362-370. doi:10.1016/S0960-8966(98)00048-0

Defour, A., Medikayala, S., Van der Meulen, J. H., Hogarth, M. W., Holdreith, N., Malatras, A., Duddy, W., Boehler, J., Nagaraju, K. and Jaiswal, J. K. (2017). Annexin A2 links poor myofiber repair with inflammation and adipogenic replacement of the injured muscle. *Hum. Mol. Genet.* **26**, 1979-1991. doi:10.1093/hmg/ddx065

Demonbreun, A. R., Rossi, A. E., Alvarez, M. G., Swanson, K. E., Deveaux, H. K., Earley, J. U., Hadhazy, M., Vohra, R., Walter, G. A., Pytel, P. et al. (2014). Dysferlin and myoferlin regulate transverse tubule formation and glycerol sensitivity. *Am. J. Pathol.* **184**, 248-259. doi:10.1016/j.ajpath.2013.09.009

Demonbreun, A. R., Wyatt, E. J., Fallon, K. S., Oosterbaan, C. C., Page, P., Hadhazy, M., Quattrocelli, M., Barefield, D. Y. and McNally, E. M. (2019). A gene-edited mouse model of Limb-Girdle muscular dystrophy 2C for testing exon skipping. *Dis. Model. Mech.* **13**, dmm040832. doi:10.1242/dmm.040832

Doetschman, T. (2009). Influence of genetic background on genetically engineered mouse phenotypes. *Methods Mol. Biol.* **530**, 423-433. doi:10.1007/978-1-59745-471-1_23

Duclos, F., Straub, V., Moore, S. A., Venzke, D. P., Hrstka, R. F., Crosbie, R. H., Durbeej, M., Lebakken, C. S., Ettinger, A. J., van der Meulen, J. et al. (1998). Progressive muscular dystrophy in alpha-sarcoglycan-deficient mice. *J. Cell Biol.* **142**, 1461-1471. doi:10.1083/jcb.142.6.1461

Durbeej, M. (2015). Laminin-alpha2 chain-deficient congenital muscular dystrophy: pathophysiology and development of treatment. *Curr. Top. Membr.* **76**, 31-60. doi:10.1016/bs.ctm.2015.05.002

Durbeej, M. and Campbell, K. P. (2002). Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models. *Curr. Opin. Genet. Dev.* **12**, 349-361. doi:10.1016/S0959-437X(02)00309-X

Durbeej, M., Conn, R. D., Hrstka, R. F., Moore, S. A., Allamand, V., Davidson, B. L., Williamson, R. A. and Campbell, K. P. (2000). Disruption of the β-sarcoglycan gene reveals pathogenetic complexity of limb-girdle muscular dystrophy type 2E. *Mol. Cell* **5**, 141-151. doi:10.1016/S1097-2765(00)80410-4

Egorova, T. V., Zotova, E. D., Reshetov, D. A., Polikarpova, A. V., Vassilieva, S. G., Vlodavets, D. V., Gavrilov, A. A., Ulianov, S. V., Buchman, V. L. and Deykin, A. V. (2019). CRISPR/Cas9-generated mouse model of Duchenne muscular dystrophy recapitulating a newly identified large 430 kb deletion in the human DMD gene. *Dis. Model. Mech.* **12**, dmm037655. doi:10.1242/dmm.037655

Emery, A. E. H. (2002). Muscular dystrophy into the new millennium. *Neuromuscul. Disord.* **12**, 343-349. doi:10.1016/S0960-8966(01)00303-0

Gawlik, K. I. and Durbeej, M. (2011). Skeletal muscle laminin and MDC1A: pathogenesis and treatment strategies. *Skelet Muscle* **1**, 9. doi:10.1186/2044-5040-1-9

Gawlik, K. I., Körner, Z., Oliveira, B. M. and Durbeej, M. (2019). Early skeletal muscle pathology and disease progress in the dy3K/dy3K mouse model of congenital muscular dystrophy with laminin α2 chain-deficiency. *Sci. Rep.* **9**, 14324. doi:10.1038/s41598-019-50550-0

Giesige, C. R., Wallace, L. M., Heller, K. N., Eidahl, J. O., Saad, N. Y., Fowler, A. M., Pyne, N. K., Al-Kharsan, M., Rashnonejad, A., Chermahini, G. A. et al. (2018). AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD. *JCI Insight* **3**, 123538. doi:10.1172/jci.insight.123538

Gordish-Dressman, H., Willmann, R., Dalle Pazze, L., Kreibich, A., van Putten, M., Heydemann, A., Bogdanik, L., Lutz, C., Davies, K., Demonbruen, A. R. et al. (2018). "Of mice and measures": a project to improve how we advance duchenne muscular dystrophy therapies to the clinic. *J. Neuromuscul. Dis.* **5**, 407-417. doi:10.3233/JND-180324

Grady, R. M., Teng, H., Nichol, M. C., Cunningham, J. C., Wilkinson, R. S. and Sanes, J. R. (1997). Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. *Cell* **90**, 729-738. doi:10.1016/S0092-8674(00)80533-4

Grounds, M. D. (2008). Two-tiered hypotheses for Duchenne muscular dystrophy. *Cell. Mol. Life Sci.* **65**, 1621-1625. doi:10.1007/s00018-008-7574-8

Grounds, M. D., Terrill, J. R., Radley-Crabb, H. G., Robertson, T., Papadimitriou, J., Spuler, S. and Shavlakadze, T. (2014). Lipid accumulation in dysferlin-deficient muscles. *Am. J. Pathol.* **184**, 1668-1676. doi:10.1016/j.ajpath.2014.02.005

Gurumurthy, C. B. and Lloyd, K. C. K. (2019). Generating mouse models for biomedical research: technological advances. *Dis. Model. Mech.* **12**, dmm029462. doi:10.1242/dmm.029462

Hack, A. A., Ly, C. T., Jiang, F., Clendenin, C. J., Sigrist, K. S., Wollmann, R. L. and McNally, E. M. (1998). γ-sarcoglycan deficiency leads to muscle membrane defects and apoptosis independent of dystrophin. *J. Cell Biol.* **142**, 1279-1287. doi:10.1083/jcb.142.5.1279

Hack, A. A., Lam, M. Y., Cordier, L., Shoturma, D. I., Ly, C. T., Hadhazy, M. R. A., Hadhazy, M. R. A., Sweeney, H. L. and McNally, E. M. (2000). Differential requirement for individual sarcoglycans and dystrophin in the assembly and function of the dystrophin-glycoprotein complex. *J. Cell Sci.* **113**, 2535-2544.

Hall, B., Limaye, A. and Kulkarni, A. B. (2009). Overview: generation of gene knockout mice. *Curr. Protoc. Cell Biol.* **44**, 19.12.1-19.12.17. doi:10.1002/0471143030.cb1912s44

Han, R., Bansal, D., Miyake, K., Muniz, V. P., Weiss, R. M., McNeil, P. L. and Campbell, K. P. (2007). Dysferlin-mediated membrane repair protects the heart from stress-induced left ventricular injury. *J. Clin. Invest.* **117**, 1805-1813. doi:10.1172/JCI30848

Han, R., Frett, E. M., Levy, J. R., Rader, E. P., Lueck, J. D., Bansal, D., Moore, S. A., Ng, R., Beltrán-Valero de Bernabé, D., Faulkner, J. A. et al. (2010). Genetic ablation of complement C3 attenuates muscle pathology in dysferlin-deficient mice. *J. Clin. Invest.* **120**, 4366-4374. doi:10.1172/JCI42390

Han, R., Rader, E. P., Levy, J. R., Bansal, D. and Campbell, K. P. (2011). Dystrophin deficiency exacerbates skeletal muscle pathology in dysferlin-null mice. *Skelet. Muscle* **I**, 35. doi:10.1186/2044-5040-1-35

Haynes, V. R., Keenan, S. N., Bayliss, J., Lloyd, E. M., Meikle, P. J., Grounds, M. D. and Watt, M. J. (2019). Dysferlin deficiency alters lipid metabolism and remodels the skeletal muscle lipidome in mice. *J. Lipid Res.* **60**, 1350-1364. doi:10.1194/jlr.M090845

Heslop, E., Csimma, C., Straub, V., McCall, J., Nagaraju, K., Wagner, K. R., Caizergues, D., Korinthenberg, R., Flanigan, K. M., Kaufmann, P. et al. (2015). The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development. *Orphanet. J. Rare. Dis.* **10**, 49. doi:10.1186/s13023-015-0258-1

Heydemann, A., Huber, J. M., Demonbreun, A., Hadhazy, M. and McNally, E. M. (2005). Genetic background influences muscular dystrophy. *Neuromuscul. Disord.* **15**, 601-609. doi:10.1016/j.nmd.2005.05.004

Ho, M., Post, C. M., Donahue, L. R., Lidov, H. G. W., Bronson, R. T., Goolsby, H., Watkins, S. C., Cox, G. A. and Brown, R. H. (2004). Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency. *Hum. Mol. Genet.* **13**, 1999-2010. doi:10.1093/hmg/ddh212

Hornsey, M. A., Laval, S. H., Barresi, R., Lochmüller, H. and Bushby, K. (2013). Muscular dystrophy in dysferlin-deficient mouse models. *Neuromuscul. Disord.* **23**, 377-387. doi:10.1016/j.nmd.2013.02.004

Im, W. B., Phelps, S. F., Copen, E. H., Adams, E. G., Slightom, J. L. and Chamberlain, J. S. (1996). Differential expression of dystrophin isoforms in

strains of mdx mice with different mutations. *Hum. Mol. Genet.* **5**, 1149-1153. doi:10.1093/hmg/5.8.1149

Jones, T. and Jones, P. L. (2018). A cre-inducible DUX4 transgenic mouse model for investigating facioscapulohumeral muscular dystrophy. *PLoS ONE* **13**, e0192657. doi:10.1371/journal.pone.0192657

Jones, T. I., Chew, G.-L., Barraza-Flores, P., Schreier, S., Ramirez, M., Wuebbles, R. D., Burkin, D. J., Bradley, R. K. and Jones, P. L. (2018). Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity. *bioRxiv* 471094. doi:10.1101/471094

Justice, M. J., Siracusa, L. D. and Stewart, A. F. (2011). Technical approaches for mouse models of human disease. *Dis. Model. Mech.* **4**, 305-310. doi:10.1242/dmm.000901

Kornegay, J. N., Spurney, C. F., Nghiem, P. P., Brinkmeyer-Langford, C. L., Hoffman, E. P. and Nagaraju, K. (2014). Pharmacologic management of duchenne muscular dystrophy: Target identification and preclinical trials. *ILAR J.* **55**, 119-149. doi:10.1093/ilar/ilu011

Krom, Y. D., Thijssen, P. E., Young, J. M., den Hamer, B., Balog, J., Yao, Z., Maves, L., Snider, L., Knopp, P., Zammit, P. S. et al. (2013). Intrinsic epigenetic regulation of the D4Z4 macrosatellite repeat in a transgenic mouse model for FSHD. *PLoS Genet.* **9**, e1003415. doi:10.1371/journal.pgen.1003415

Kuang, W., Xu, H., Vachon, P. H., Liu, L., Loechel, F., Wewer, U. M. and Engvall, E. (1998a). Merosin-deficient congenital muscular dystrophy. Partial genetic correction in two mouse models. *J. Clin. Invest.* **102**, 844-852. doi:10.1172/JCI3705

Kuang, W., Xu, H., Vachon, P. H. and Engvall, E. (1998b). Disruption of the lama2 gene in embryonic stem cells: Laminin α2 is necessary for sustenance of mature muscle cells. *Exp. Cell Res.* **241**, 117-125. doi:10.1006/excr.1998.4025

Kudoh, H., Ikeda, H., Kakitani, M., Ueda, A., Hayasaka, M., Tomizuka, K. and Hanaoka, K. (2005). A new model mouse for Duchenne muscular dystrophy produced by 2.4 Mb deletion of dystrophin gene using Cre-loxP recombination system. *Biochem. Biophys. Res. Commun.* **328**, 507-516. doi:10.1016/j.bbrc.2004.12.191

Leidenroth, A. and Hewitt, J. E. (2010). A family history of DUX4: phylogenetic analysis of DUXA, B, C and Duxbl reveals the ancestral DUX gene. *BMC Evol. Biol.* **10**, 364. doi:10.1186/1471-2148-10-364

Lek, A., Rahimov, F., Jones, P. L. and Kunkel, L. M. (2015). Emerging preclinical animal models for FSHD. *Trends Mol. Med.* **21**, 295-306. doi:10.1016/j.molmed.2015.02.011

Lostal, W., Bartoli, M., Bourg, N., Roudaut, C., Bentaïb, A., Miyake, K., Guerchet, N., Fougerousse, F., McNeil, P. and Richard, I. (2010). Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer. *Hum. Mol. Genet.* **19**, 1897-1907. doi:10.1093/hmg/ddq065

Mantuano, P., Sanarica, F., Conte, E., Morgese, M. G., Capogrosso, R. F., Cozzoli, A., Fonzino, A., Quaranta, A., Rolland, J.-F., De Bellis, M. et al. (2018). Effect of a long-term treatment with metformin in dystrophic mdx mice: a reconsideration of its potential clinical interest in Duchenne muscular dystrophy. *Biochem. Pharmacol.* **154**, 89-103. doi:10.1016/j.bcp.2018.04.022

McGreevy, J. W., Hakim, C. H., McIntosh, M. A. and Duan, D. (2015). Animal models of Duchenne muscular dystrophy: From basic mechanisms to gene therapy. *DMM Dis. Model. Mech.* **8**, 195-213. doi:10.1242/dmm.018424

Meier, H. and Southard, J. L. (1970). Muscular dystrophy in the mouse caused by an allele at the dy-locus. *Life Sci.* **9**, 137-144. doi:10.1016/0024-3205(70)90306-1

Mele, A., Mantuano, P., De Bellis, M., Rana, F., Sanarica, F., Conte, E., Morgese, M. G., Bove, M., Rolland, J.-F., Capogrosso, R. F. et al. (2019). A long-term treatment with taurine prevents cardiac dysfunction in mdx mice. *Transl. Res.* **204**, 82-99. doi:10.1016/j.trsl.2018.09.004

Mercuri, E. and Muntoni, F. (2013). Muscular dystrophies. *Lancet* **381**, 845-860. doi:10.1016/S0140-6736(12)61897-2

Michelson, A. M., Russell, E. S. and Harman, P. J. (1955). Dystrophia muscularis: a hereditary primary myopathy in the house mouse. *Proc. Natl. Acad. Sci. USA* **41**, 1079-1084. doi:10.1073/pnas.41.12.1079

Miyagoe, Y., Hanaoka, K., Nonaka, I., Hayasaka, M., Nabeshima, Y., Arahata, K., Nabeshima, Y. and Takeda, S. (1997). Laminin alpha2 chain-null mutant mice by targeted disruption of the Lama2 gene: a new model of merosin (laminin 2)-deficient congenital muscular dystrophy. *FEBS Lett.* **415**, 33-39. doi:10.1016/S0014-5793(97)01007-7

Mourkioti, F., Kustan, J., Kraft, P., Day, J. W., Zhao, M. M., Kost-Alimova, M., Protopopov, A., Depinho, R. A., Bernstein, D., Meeker, A. K. et al. (2013). Role of telomere dysfunction in cardiac failure in Duchenne muscular dystrophy. *Nat. Cell Biol.* **15**, 895-904. doi:10.1038/ncb2790

Mueller, A. L., O'Neill, A., Jones, T. I., Llach, A., Rojas, L. A., Sakellariou, P., Stadler, G., Wright, W. E., Eyerman, D., Jones, P. L. et al. (2019). Muscle xenografts reproduce key molecular features of facioscapulohumeral muscular dystrophy. *Exp. Neurol.* **320**, 113011. doi:10.1016/j.expneurol.2019.113011

Nagaraju, K. and Willmann, R. and TREAT-NMD Network and the Wellstone Muscular Dystrophy Cooperative Research Network (2009). Developing standard procedures for murine and canine efficacy studies of DMD therapeutics: report of two expert workshops on "Pre-clinical testing for Duchenne dystrophy": Washington DC, October 27th-28th 2007 and Zurich, June 30th-July 1st 2008. *Neuromuscul. Disord.* **19**, 502-506. doi:10.1016/j.nmd.2009.05.003

Olie, C. S., Riaz, M., Konietzny, R., Charles, P. D., Pinto-Fernandez, A., Kiełbasa, S. M., Aartsma-Rus, A., Goeman, J. J., Kessler, B. M. and Raz, V. (2019). Deacetylation inhibition reverses PABPN1-dependent muscle wasting. *iScience* **12**, 318-332. doi:10.1016/j.isci.2019.01.024

Pasteuning-Vuhman, S., Putker, K., Tanganyika-De Winter, C. L., Boertje-Van Der Meulen, J. W., Van Vliet, L., Overzier, M., Plomp, J. J., Aartsma-Rus, A. and Van Putten, M. (2017). Natural disease history of mouse models for limb girdle muscular dystrophy types 2D and 2F. *PLoS ONE* **12**, e0182704. doi:10.1371/journal.pone.0182704

Pasteuning-Vuhman, S., Putker, K., Tanganyika-de Winter, C. L., Boertje-van der Meulen, J. W., Van Vliet, L., Overzier, M., Plomp, J. J., Aartsma-Rus, A. and Van Putten, M. (2018). Natural disease history of the dy^{2J}mouse model of laminin α2 (merosin)-deficient congenital muscular dystrophy. *PLoS ONE* **13**, e0197388. doi:10.1371/journal.pone.0197388

Patton, B. L., Wang, B., Tarumi, Y. S., Seburn, K. L. and Burgess, R. W. (2008). A single point mutation in the LN domain of LAMA2 causes muscular dystrophy and peripheral amyelination. *J. Cell Sci.* **121**, 1593-1604. doi:10.1242/jcs.015354

Raz, Y. and Raz, V. (2014). Oculopharyngeal muscular dystrophy as a paradigm for muscle aging. *Front. Aging Neurosci.* **6**, 317. doi:10.3389/fnagi.2014.00317

Reinhard, J. R., Lin, S., McKee, K. K., Meinen, S., Crosson, S. C., Sury, M., Hobbs, S., Maier, G., Yurchenco, P. D. and Rüegg, M. A. (2017). Linker proteins restore basement membrane and correct LAMA2-related muscular dystrophy in mice. *Sci. Transl. Med.* **9**, eaal4649. doi:10.1126/scitranslmed.aal4649

Riaz, M., Raz, Y., van Putten, M., Paniagua-Soriano, G., Krom, Y. D., Florea, B. I. B. I. and Raz, V. (2016). PABPN1-dependent mRNA processing induces muscle wasting. *PLoS Genet.* **12**, e1006031. doi:10.1371/journal.pgen.1006031

Sacco, A., Mourkioti, F., Tran, R., Choi, J., Llewellyn, M., Kraft, P., Shkreli, M., Delp, S., Pomerantz, J. H., Artandi, S. E. et al. (2010). Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx/mTR mice. *Cell* **143**, 1059-1071. doi:10.1016/j.cell.2010.11.039

Sakellariou, P., O'Neill, A., Mueller, A. L., Stadler, G., Wright, W. E., Roche, J. A. and Bloch, R. J. (2016). Neuromuscular electrical stimulation promotes development in mice of mature human muscle from immortalized human myoblasts. *Skelet. Muscle* **6**, 4. doi:10.1186/s13395-016-0078-6

Sasaoka, T., Imamura, M., Araishi, K., Noguchi, S., Mizuno, Y., Takagoshi, N., Hama, H., Wakabayashi-Takai, E., Yoshimoto-Matsuda, Y., Nonaka, I. et al. (2003). Pathological analysis of muscle hypertrophy and degeneration in muscular dystrophy in γ-sarcoglycan-deficient mice. *Neuromuscul. Disord.* **13**, 193-206. doi:10.1016/s0960-8966(02)00220-1

Saunier, M., Bönnemann, C. G., Durbeej, M., Allamand, V., Bönnemann, C. G., Durbeej, M. and Allamand, V. and CMD Animal Model Consortium (2016). 212th ENMC International Workshop: Animal models of congenital muscular dystrophies, Naarden, The Netherlands, 29-31 May 2015. *Neuromuscul. Disord.* **26**, 252-259. doi:10.1016/j.nmd.2016.02.002

Sellers, S. L., Milad, N., White, Z., Pascoe, C., Chan, R., Payne, G. W., Seow, C., Rossi, F., Seidman, M. A. and Bernatchez, P. (2018). Increased nonHDL cholesterol levels cause muscle wasting and ambulatory dysfunction in the mouse model of LGMD2B. *J. Lipid Res.* **59**, 261-272. doi:10.1194/jlr.M079459

Stottmann, R. and Beier, D. (2014). ENU mutagenesis in the mouse. *Curr. Protoc. Hum. Genet.* **2014**, 15.4.1-15.4.10. doi:10.1002/0471142905.hg1504s82

Straub, V. and Mercuri, E. (2018). Report on the workshop: Meaningful outcome measures for Duchenne muscular dystrophy, London, UK, 30–31 January 2017. *Neuromuscul. Disord.* **28**, 690-701. doi:10.1016/j.nmd.2018.05.013

Straub, V., Murphy, A. and Udd, B. (2018). 229th ENMC international workshop: Limb girdle muscular dystrophies – Nomenclature and reformed classification Naarden, the Netherlands, 17–19 March 2017. *Neuromuscul. Disord.* **28**, 702-710. doi:10.1016/j.nmd.2018.05.007

Sunada, Y., Bernier, S. M., Utani, A., Yamada, Y. and Campbell, K. P. (1995). Identification of a novel mutant transcript of laminin alpha 2 chain gene responsible for muscular dystrophy and dysmyelination in dy2J mice. *Hum. Mol. Genet.* **4**, 1055-1061. doi:10.1093/hmg/4.6.1055

Tam, C. S., Power, J. E., Markovic, T. P., Yee, C., Morsch, M., McLennan, S. V. and Twigg, S. M. (2015). The effects of high-fat feeding on physical function and skeletal muscle extracellular matrix. *Nutr. Diabetes* **5**, e187. doi:10.1038/nutd.2015.39

Terrill, J. R., Radley-Crabb, H. G., Iwasaki, T., Lemckert, F. A., Arthur, P. G. and Grounds, M. D. (2013). Oxidative stress and pathology in muscular dystrophies: focus on protein thiol oxidation and dysferlinopathies. *FEBS J.* **280**, 4149-4164. doi:10.1111/febs.12142

Trollet, C., Gidaro, T., Klein, P., Périé, S., Butler-Browne, G. and Lacau St Guily, J. (1993). *Oculopharyngeal Muscular Dystrophy*. New York, NY: Springer New York.

Trollet, C., Anvar, S. Y., Venema, A., Hargreaves, I. P., Foster, K., Vignaud, A., Ferry, A., Negroni, E., Hourde, C., Baraibar, M. A. et al. (2010). Molecular and phenotypic characterization of a mouse model of oculopharyngeal muscular dystrophy reveals severe muscular atrophy restricted to fast glycolytic fibres. *Hum. Mol. Genet.* **19**, 2191-2207. doi:10.1093/hmg/ddq098

van der Pijl, E. M., van Putten, M., Niks, E. H., Verschuuren, J. J. G. M., Aartsma-Rus, A. and Plomp, J. J. (2016). Characterization of neuromuscular synapse function abnormalities in multiple Duchenne muscular dystrophy mouse models. *Eur. J. Neurosci.* **43**, 1623-1635. doi:10.1111/ejn.13249

van Putten, M., Putker, K., Overzier, M., Adamzek, W. A., Pasteuning-Vuhman, S., Plomp, J. J. and Aartsma-Rus, A. (2019). Natural disease history of the D2-mdx mouse model for Duchenne muscular dystrophy. *FASEB J.* **33**, 8110-8124. doi:10.1096/fj.201802488R

Veltrop, M., van der Kaa, J., Claassens, J., van Vliet, L., Verbeek, S. and Aartsma-Rus, A. (2013). Generation of embryonic stem cells and mice for duchenne research. *PLoS Curr.* **5**, ecurrents.md.cbf1d33001de80923ce674302cad7925. doi:10.1371/currents.md.cbf1d33001de80923ce674302cad7925

Veltrop, M., Van Vliet, L., Hulsker, M., Claassens, J., Brouwers, C., Breukel, C., Van der Kaa, J., Linssen, M. M., den Dunnen, J. T., Verbeek, S. et al. (2018). A dystrophic Duchenne mouse model for testing human antisense oligonucleotides. *PLoS ONE* **13**, e0193289. doi:10.1371/journal.pone.0193289

Verhaart, I. E. C. and Aartsma-Rus, A. (2019). Therapeutic developments for Duchenne muscular dystrophy. *Nat. Rev. Neurol.* **15**, 373-386. doi:10.1038/s41582-019-0203-3

Verhaart, I. E. C., Putker, K., van de Vijver, D., Tanganyika-de Winter, C. L., Pasteuning-Vuhman, S., Plomp, J. J., Aartsma-Rus, A. M. and van Putten, M. (2019). Cross-sectional study into age-related pathology of mouse models for limb girdle muscular dystrophy types 2D and 2F. *PLoS ONE* **14**, e0220665. doi:10.1371/journal.pone.0220665

Vest, K. E., Phillips, B. L., Banerjee, A., Apponi, L. H., Dammer, E. B., Xu, W., Zheng, D., Yu, J., Tian, B., Pavlath, G. K. et al. (2017). Novel mouse models of oculopharyngeal muscular dystrophy (OPMD) reveal early onset mitochondrial defects and suggest loss of PABPN1 may contribute to pathology. *Hum. Mol. Genet.* **26**, 3235-3252. doi:10.1093/hmg/ddx206

Weller, A. H., Magliato, S. A., Bell, K. P. and Rosenberg, N. L. (1997). Spontaneous myopathy in the SJL/J mouse: Pathology and strength loss. *Muscle Nerve* **20**, 72-82. doi:10.1002/(SICI)1097-4598(199701)20:1<72::AID-MUS10>3.0.CO;2-3

Willmann, R., Possekel, S., Dubach-Powell, J., Meier, T. and Ruegg, M. A. (2009). Mammalian animal models for Duchenne muscular dystrophy. *Neuromuscul. Disord.* **19**, 241-249. doi:10.1016/j.nmd.2008.11.015

Willmann, R., De Luca, A., Benatar, M., Grounds, M., Dubach, J., Raymackers, J.-M. and Nagaraju, K. (2011a). Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice. *Neuromuscul. Disord.* **22**, 43-49. doi:10.1016/j.nmd.2011.04.012

Willmann, R., Dubach, J. and Chen, K. (2011b). Developing standard procedures for pre-clinical efficacy studies in mouse models of spinal muscular atrophy: report of the expert workshop "Pre-clinical testing for SMA", Zurich, March 29-30th 2010. *Neuromuscul. Disord.* **21**, 74-77. doi:10.1016/j.nmd.2010.09.014

Willmann, R., Gordish-Dressman, H., Meinen, S., Rüegg, M. A., Yu, Q., Nagaraju, K., Kumar, A., Girgenrath, M., Coffey, C. B. M., Cruz, V. et al. (2017). Improving reproducibility of phenotypic assessments in the DyW mouse model of laminin-α2 related congenital muscular dystrophy. *J. Neuromuscul. Dis.* **4**, 115-126. doi:10.3233/JND-170217

Wood, C. L., Suchaki, K. J., van 't Hof, R., Cawthorn, W. P., Dillon, S., Straub, V., Wong, S. C., Ahmed, S. F. and Farquharson, C. (2020). A comparison of the bone and growth phenotype of *mdx*, *mdx:Cmah*[−/−] and *mdx:Utrn*[+/−] murine models with the C57BL/10 wild-type mouse. *Dis. Model. Mech.* **13**, dmm040659. doi:10.1242/dmm.040659

Xu, H., Wu, X.-R., Wewer, U. M. and Engvall, E. (1994). Murine muscular dystrophy caused by a mutation in the laminin alpha 2 (Lama2) gene. *Nat. Genet.* **8**, 297-302. doi:10.1038/ng1194-297

Young, C. S., Mokhonova, E., Quinonez, M., Pyle, A. D. and Spencer, M. J. (2017). Creation of a novel humanized dystrophic mouse model of duchenne muscular dystrophy and application of a CRISPR/Cas9 gene editing therapy. *J. Neuromuscul Dis.* **4**, 139-145. doi:10.3233/JND-170218

Zhang, Y., King, O. D., Rahimov, F., Jones, T. I., Ward, C. W., Kerr, J. P., Liu, N., Emerson, C. P., Kunkel, L. M., Partridge, T. A. et al. (2014). Humanskeletal musclexenograft as anewpreclinical model for muscle disorders. *Hum. Mol. Genet.* **23**, 3180-3188. doi:10.1093/hmg/ddu028

Zschüntzsch, J., Zhang, Y., Klinker, F., Makosch, G., Klinge, L., Malzahn, D., Brinkmeier, H., Liebetanz, D. and Schmidt, J. (2016). Treatment with human immunoglobulin G improves the early disease course in a mouse model of Duchenne muscular dystrophy. *J. Neurochem.* **136**, 351-362. doi:10.1111/jnc.13269